Basilea Pharmaceutica AG Allschwil
SWB:PK5
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Basilea Pharmaceutica AG Allschwil
SWB:PK5
|
CH |
|
S
|
Sam Holdings Corp
VN:SAM
|
VN |
|
S
|
Semperit Holding AG
VSE:SEM
|
AT |
|
W
|
Wang Zheng Bhd
KLSE:WANGZNG
|
MY |
|
Telstra Corporation Ltd
ASX:TLS
|
AU |
|
Minda Corporation Ltd
NSE:MINDACORP
|
IN |
|
Magna International Inc
TSX:MG
|
CA |
|
SCS Group PLC
LSE:SCS
|
UK |
|
Aether Catalyst Solutions Inc
OTC:ATHHF
|
CA |
|
O
|
Oriental Hotels Ltd
NSE:ORIENTHOT
|
IN |
|
S
|
Siemens AG
OTC:SMAWF
|
DE |
|
Heidelberger Druckmaschinen AG
XETRA:HDD
|
DE |
|
S
|
Seoul Semiconductor Co Ltd
KOSDAQ:046890
|
KR |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is PK5's stock price target?
Not Available
PK5 doesn't have any price targets made by Wall Street professionals.
What is Basilea Pharmaceutica AG Allschwil's Revenue forecast?
Projected CAGR
-5%
For the last 14 years the compound annual growth rate for Basilea Pharmaceutica AG Allschwil's revenue is 9%. The projected CAGR for the next 3 years is -5%.
What is Basilea Pharmaceutica AG Allschwil's Operating Income forecast?
Projected CAGR
-39%
The compound annual growth rate of Basilea Pharmaceutica AG Allschwil's operating income for the next 3 years is -39%.
What is Basilea Pharmaceutica AG Allschwil's Net Income forecast?
Projected CAGR
-33%
The compound annual growth rate of Basilea Pharmaceutica AG Allschwil's net income for the next 3 years is -33%.
